Bliss GVS Pharma Ltd - 506197 - Intimation Of Record Date In Accordance With Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (''Listing Regulations'')
Bliss GVS Pharma fixed July 08, 2026, as the Record Date for its Final Dividend for FY26. Eligible shareholders will receive payment by August 14, 2026, with book closure from July 09-15, 2026.
Jun 23 2026 18:30:24
Bliss GVS Pharma Ltd - 506197 - Communication To Shareholders - Intimation Of Tax Deduction On Dividend
Bliss GVS Pharma issued a communication regarding the tax deduction at source (TDS) procedures for the recommended Re. 1.00 final dividend for FY 2025-26. Shareholders must submit relevant tax documents by July 08, 2026, to ensure appropriate TDS.
Jun 19 2026 19:31:03
Bliss GVS Pharma Ltd - 506197 - Submission Of Draft Letter Of Offer In Relation To The Open Offer Made To The Public Shareholders Of Bliss GVS Pharma Limited Under The SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011
Bliss GVS Pharma informed about the filing of a draft letter of offer for a mandatory open offer by Anupam Rasayan India Limited. The offer is to acquire up to 26.00% of the company's expanded voting share capital at an offer price of Rs. 299.00 per share, with a total consideration of approximately Rs. 829 crore, triggered by an acquisition for control.
Jun 09 2026 19:27:05
Bliss GVS Pharma Ltd - 506197 - Draft Letter of Offer
Anupam Rasayan India Limited (Acquirer) announced a mandatory open offer to acquire up to 26.00% of Bliss GVS Pharma's expanded voting share capital from public shareholders at Rs.299 per equity share. The total consideration for this offer, assuming full acceptance, is Rs.829.03 crore. The tendering period for the offer will be from July 16, 2026, to July 29, 2026.
Jun 09 2026 10:19:37
Bliss GVS Pharma Ltd - 506197 - Intimation Of WHO-GMP Compliance Of Manufacturing Facility
Bliss GVS Pharma's Palghar manufacturing facility has received an Inspection Closure Report from the World Health Organization (WHO), confirming compliance with Good Manufacturing Practices (GMP) standards. This achievement underscores the company's commitment to quality and operational excellence in pharmaceutical production.
Jun 02 2026 19:28:45
Bliss GVS Pharma Ltd - 506197 - Detailed Public Statement
Anupam Rasayan India Limited has launched an open offer to acquire up to 26% of Bliss GVS Pharma's equity for ₹829.03 crore. The offer price of ₹299 per share represents a 20.78% premium over the 60-day volume-weighted average price, triggering a change in control.
Jun 01 2026 19:50:31
Bliss GVS Pharma Ltd - 506197 - Detailed Public Statement In Relation To Open Offer Made To The Public Shareholders Of The Company
Bliss GVS Pharma has received a detailed public statement regarding an open offer from Anupam Rasayan India Ltd. The acquirer will acquire up to 26% stake at Rs.299 per share, totaling Rs.829.03 crore. This follows an agreement to acquire 43.30% control of the company.
Jun 01 2026 18:54:53
Read More